Pages that link to "Q68100919"

The following pages link to Mercedes Fernández (Q68100919):

Displaying 31 items.

• Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane (Q35045371) (← links)
• Hepatic, splanchnic and systemic haemodynamic abnormalities in portal hypertension (Q35465887) (← links)
• NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats. (Q35761411) (← links)
• Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. (Q37766339) (← links)
• Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease. (Q38815138) (← links)
• Molecular pathophysiology of portal hypertension. (Q39148718) (← links)
• New approaches in the pharmacologic treatment of portal hypertension. (Q40709930) (← links)
• Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. (Q42245190) (← links)
• Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. (Q42275656) (← links)
• Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension. (Q43141347) (← links)
• Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity. (Q43672258) (← links)
• Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. (Q44675023) (← links)
• Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. (Q44779682) (← links)
• Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. (Q48026378) (← links)
• Neonatal capsaicin treatment does not prevent splanchnic vasodilatation in portal-hypertensive rats. (Q51617775) (← links)
• Pathophysiology of portal hypertension. (Q54274405) (← links)
• Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats (Q57145837) (← links)
• The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis (Q62078862) (← links)
• Alterations in soluble and leukocyte surface L-selectin (CD 62L) in hemodialysis patients (Q70971722) (← links)
• Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis (Q71035939) (← links)
• Mechanical pumping of portal blood to the liver: hemodynamic effects of a new experimental treatment for portal hypertension (Q71605623) (← links)
• Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis (Q72371473) (← links)
• Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation (Q72402216) (← links)
• Gastric microcirculatory changes of portal-hypertensive rats can be attenuated by long-term estrogen-progestagen treatment (Q72719885) (← links)
• Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation (Q72853759) (← links)
• Duration of the hemodynamic effects of N(G)-nitro-L-arginine methyl ester in vivo (Q73843231) (← links)
• Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats (Q77807952) (← links)
• Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats (Q80678101) (← links)
• Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats (Q82471490) (← links)
• Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats (Q83612487) (← links)
• Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension (Q87475232) (← links)